Bristol-Myers Squibb, the New York-based drugmaker, said sales fell 4% to $3.9 billion in the third quarter of 2014 as three of its top-selling drugs reported double-digit declines in revenue.
But profits still rose during the quarter by 4% to $721 million compared with the same quarter in 2013.
The company saw a 14% decline in sales for chronic hepatitis B treatment Baraclude to $325 million, while HIV/AIDs therapy Reyataz dropped 10% in sales to $338 million, and antipsychotic Abilify reported a 21% drop in sales to $449 million.
But some of the company's newer oncology products reported strong growth for the quarter. Revenue for Yervoy, the melanoma drug approved by the Food and Drug Administration in 2011, rose 47% to $350 million and sales of Sprycel, a leukemia medicine, jumped 22% to $285 million.
Bristol-Myers Squibb said marketing, selling and administrative costs rose 5% to $1 billion, while advertising and product promotion spending fell 12% to $171 million.
The manufacturer adjusted its guidance for 2015, saying it expects revenue between $15.2 billion and $15.8 billion.
Follow Jaimy Lee on Twitter: @MHjlee
Send us a letter
Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.
